High Fibrinopeptide A (FPA) Levels in Acute Non-Lymphocytic Leukemia Are Reduced by Heparin Administration

Summary

Plasma levels of fibrinopeptide A (FPA) in 30 untreated patients with acute non-lymphocytic leukemia (ANLL) were significantly higher than in 30 healthy controls (p <0.001). Patients without laboratory signs of disseminated intravascular coagulation (DIC) had levels of FPA higher than controls (p <0.02) but markedly lower than patients with DIC (p <0.001). Five patients with M₃ leukemia had a higher mean FPA level (p <0.02) and a lower peripheral blast cell count (p <0.05) than patients with other cytological subtypes of ANLL. When patients with M₃ were excluded, a significant correlation was observed between the peripheral blast cell counts and the FPA levels (r = 0.66, p <0.001). FPA levels were similar with body temperature either above or below 38° C. After intravenous bolus of heparin FPA dropped to normal levels in 14 out of 17 patients who had high baseline values. These findings indicate that intravascular thrombin formation, which probably result from the expression of procoagulant activities of blast cells, is the main cause of high FPA in the majority of patients with acute non-lymphocytic leukemia.

Key words

Fibrinopeptide A (FPA) - Acute leukemia - Heparin

• References

• 1 Nossel HL, Yudelman I, Canfield RE, Butler VP, Spanondis K, Wilner GD, Quareshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-53
• 2 Nossel HL, Ti M, Kaplan KL, Spanondis K, Soland T, Butler VP. The generation of fibrinopeptide A in clinical blood samples. Evidence for thrombin activity J Clin Invest 1976; 58: 1136-1144
• 3 Myers TJ, Rickies FR, Barb C, Cronlund M. Fibrinopeptide A in Acute Leukemia: relationship of activation of blood coagulation to disease activity. Blood 1981; 57: 518-524
• 4 Mombelli G, Roux A, Haeberli A, Straub PW. Comparison of ¹²⁵I- Fibrinogen kinetics and fibrinopeptide A in patients with disseminated neoplasias. Blood 1982; 60: 381-388
• 5 Peuscher FW, Cleton FJ, Armstrong L, Stoepman van Dalen EA, van Mourik JA, van Aken WG. Significance of plasma fibrinopeptide A (FPA) in patients with malignancy. J Lab Clin Med 1980; 96: 5-14
• 6 Yuldelman I, Greenberg J. Factors affecting fibrinopeptide-A levels in patients with venous thromboembolism during anticoagulant therapy. Blood 1982; 59: 787-792
• 7 Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galton MR, Gralnick MR, Sultan C. French-American-British (FAB) Cooperative Group. Proposal for the classification of the acute leukemia Br J Haematol 1976; 33: 451-458
• 8 Godal MC, Abildgaard N. Gelation of soluble fibrin in plasma by ethanol. Scand J Haematol 1966; 3: 342-350
• 9 Latallo ZG, Wergarzynowicz Z, Teissyre E, Kopec M. Simple and rapid evaluation of the intravascular coagulation and fibrinolytic states by application of protamine sulphate and reptilase-R. Scand J Haematol 1971; 13: 387-392
• 10 Viganò S, Cattaneo M, Gervasoni W, Mannucci PM. Increased fibrinopeptide A after prothrombin complex concentrates. Thromb Haemostas 1980; 44: 72-75
• 11 Gralnick MR, Abrell E. Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukemia. Br J Haematol 1973; 24: 89-99
• 12 Arlin AZ, Fried J, Clarkson BD. Therapeutic role of cell kinetics in acute leukemia. Clin Haematol 1978; 7: 339-362